What is tenosynovial
giant cell tumor (TGCT)?

TGCT is also formerly known as pigmented villonodular synovitis (PVNS) or giant cell tumor of the tendon sheath (GCT-TS)

TGCT is a chronic disease where tumors form in the body's joints causing pain, swelling, and loss of range of motion in the affected joint. TGCT may cause permanent damage to the joint.*

*In a study of patients with diffuse TGCT, 8 out of 45 patients (18%) who did not have osteoarthritis at baseline developed signs of joint damage.

11-50 casesper million people annually

33 years of agethe median age of diagnosis

A mother and her toddler playing with toys

There are two types of TGCT:

Localized/nodular TGCT is more common and tends to be smaller, well‑defined tumors inside or outside of the joint.

Diffuse TGCT is less common and tends to be larger tumors with ill‑defined boundaries.

High recurrence can potentially create lifelong burdens

up to72%recurrence rate
for diffuse

up to15%recurrence rate for
localized/nodular

TGCT can have a major impact on daily living

92%of patients
reported pain

A leg experiencing a limited range of motion

85%of patients reported
limited range of motion

In a recent study of people living with TGCT^†

~55%of patientshad their symptoms come back, even after surgery

^†This study is from the TGCT Support Registry, the largest registry of TGCT patients. 497 adults were included in the analysis.

A father pushing his daughter on a swing

Treating TGCT: surgery or prescription medicines?

While TGCT is often treated with surgery, surgery isn't right for everyone, and not all tumors can be removed.

Want to learn more about TGCT?

TGCT Support has information, statistics, support, and resources to help you better understand the condition.^‡

Visit TGCT Support

^‡TGCT Support is an independent group that is not affiliated with Deciphera.

Important Safety Information

What is the most important information I should know about ROMVIMZA?

ROMVIMZA can cause serious side effects, including liver problems. Increased liver enzymes in your blood are common with ROMVIMZA.

Your healthcare provider will do blood tests to check for liver problems:

before starting treatment with ROMVIMZA,
2 times each month for the first 2 months of treatment,
then 1 time every 3 months for the first year of treatment and as clinically indicated thereafter.

If you develop liver problems during treatment with ROMVIMZA, your healthcare provider may temporarily stop treatment, decrease your dose, or permanently stop treatment depending on how severe your liver problems are.

Tell your healthcare provider right away if you develop any signs or symptoms of liver problems during treatment with ROMVIMZA including yellowing of your skin or the white part of your eyes, dark urine, lack or loss of appetite, right upper stomach‑area (abdomen) pain or tenderness, feeling overly tired, nausea, vomiting, fever, rash, and itching.

Before taking ROMVIMZA, tell your healthcare provider about all of your medical conditions, including if you:

have or had liver problems.
are pregnant or plan to become pregnant. ROMVIMZA can harm your unborn baby.

Females who are able to become pregnant:

Your healthcare provider will do a pregnancy test before you start treatment with ROMVIMZA.
Use effective birth control (contraception) during treatment with ROMVIMZA and for 1 month after the last dose. Talk to your healthcare provider about birth control methods that may be right for you.
Tell your healthcare provider right away if you become pregnant or you think you may be pregnant during treatment with ROMVIMZA.

Males with female partners who are able to become pregnant:

Use effective birth control (contraception) during treatment with ROMVIMZA and for 1 month after the last dose.
Tell your healthcare provider right away if your female partner becomes pregnant or thinks she may be pregnant during treatment with ROMVIMZA.

are breastfeeding or plan to breastfeed. It is not known if ROMVIMZA passes into your breast milk. Do not breastfeed during treatment with ROMVIMZA and for 1 month after the last dose.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Taking ROMVIMZA with certain other medicines may affect the way that ROMVIMZA or the other medicine works and may increase your risk of side effects.

What are the possible side effects of ROMVIMZA?

ROMVIMZA can cause serious side effects.

Allergic reactions to FD&C Yellow No. 5 and FD&C Yellow No. 6. ROMVIMZA 20 mg capsules contain the inactive ingredients FD&C Yellow No. 5 (tartrazine) and FD&C Yellow No. 6 (Sunset Yellow FCF). ROMVIMZA 14 mg capsules contain the inactive ingredient FD&C Yellow No. 6 (Sunset Yellow FCF). FD&C Yellow No. 5 (tartrazine) can cause allergic-type reactions (including bronchial asthma) in certain people, especially people who also have an allergy to aspirin. FD&C Yellow No. 6 (Sunset Yellow FCF) can also cause allergic reactions. Tell your healthcare provider if you get hives, rash, or trouble breathing during treatment with ROMVIMZA.

The most common side effects of ROMVIMZA include:

swelling around your eyes
tiredness
rash
increased cholesterol levels in your blood

swelling of your hands or feet
swelling of your face
decreased white blood cells
itchy skin

ROMVIMZA may cause fertility problems, which may affect your ability to have children. Talk to your healthcare provider if you have concerns about fertility.

These are not all the possible side effects of ROMVIMZA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is ROMVIMZA?

ROMVIMZA is a prescription medicine used to treat adults with symptomatic tenosynovial giant cell tumor (TGCT) when surgery may make the symptoms worse or cause severe problems.

It is not known if ROMVIMZA is safe and effective in children.

Please click for the full Prescribing Information, including Medication Guide.